Literature DB >> 3233054

Effect of ibogaine on naloxone-precipitated withdrawal syndrome in chronic morphine-dependent rats.

E D Dzoljic1, C D Kaplan, M R Dzoljic.   

Abstract

Ibogaine, an indole alkaloid, administered intracerebroventricularly 4-16 micrograms, attenuated a naloxone-precipitated withdrawal syndrome in chronic morphine-dependent rats. It appears that ibogaine has a more consistent effect on certain selective withdrawal signs related to the locomotion. This might explain an attenuating effect of ibogaine on some withdrawal signs. However, due to complex interaction of ibogaine with serotonin and other neurotransmitter systems, the mechanism of ibogaine antiwithdrawal effect remains unknown and requires further elucidation.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3233054

Source DB:  PubMed          Journal:  Arch Int Pharmacodyn Ther        ISSN： 0003-9780


  12 in total

Review 1.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

2.  Pharmacological screen for activities of 12-hydroxyibogamine: a primary metabolite of the indole alkaloid ibogaine.

Authors:  J K Staley; Q Ouyang; J Pablo; W L Hearn; D D Flynn; R B Rothman; K C Rice; D C Mash
Journal:  Psychopharmacology (Berl)       Date:  1996-09       Impact factor: 4.530

3.  Long-lasting ibogaine protection against NMDA-induced convulsions in mice.

Authors:  M B Leal; D O de Souza; E Elisabetsky
Journal:  Neurochem Res       Date:  2000-08       Impact factor: 3.996

Review 4.  Non-Opioid Neurotransmitter Systems that Contribute to the Opioid Withdrawal Syndrome: A Review of Preclinical and Human Evidence.

Authors:  Kelly E Dunn; Andrew S Huhn; Cecilia L Bergeria; Cassandra D Gipson; Elise M Weerts
Journal:  J Pharmacol Exp Ther       Date:  2019-08-07       Impact factor: 4.030

5.  2-MPPA, a selective glutamate carboxypeptidase II inhibitor, attenuates morphine tolerance but not dependence in C57/Bl mice.

Authors:  Ewa Kozela; Malgorzata Wrobel; Tomasz Kos; Jacek Wojcikowski; Wladyslawa A Daniel; Krystyna M Wozniak; Barbara S Slusher; Piotr Popik
Journal:  Psychopharmacology (Berl)       Date:  2005-10-12       Impact factor: 4.530

Review 6.  The adverse events of ibogaine in humans: an updated systematic review of the literature (2015-2020).

Authors:  Genís Ona; Juliana Mendes Rocha; José Carlos Bouso; Jaime E C Hallak; Tre Borràs; Maria Teresa Colomina; Rafael G Dos Santos
Journal:  Psychopharmacology (Berl)       Date:  2021-08-18       Impact factor: 4.530

7.  Neurochemical and behavioural interactions between ibogaine and nicotine in the rat.

Authors:  M E Benwell; P E Holtom; R J Moran; D J Balfour
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

8.  Towards a Role for Clinical Pathology Diagnostics for Childhood Maltreatment.

Authors:  E L Bearer; J Ji; P Trickett; C D Kaplan; F Mennen
Journal:  Austin J Clin Pathol       Date:  2015-09-29

9.  Effects of ibogaine on responding maintained by food, cocaine and heroin reinforcement in rats.

Authors:  S I Dworkin; S Gleeson; D Meloni; T R Koves; T J Martin
Journal:  Psychopharmacology (Berl)       Date:  1995-02       Impact factor: 4.530

10.  EEG Gamma Band Alterations and REM-like Traits Underpin the Acute Effect of the Atypical Psychedelic Ibogaine in the Rat.

Authors:  Joaquín González; Matias Cavelli; Santiago Castro-Zaballa; Alejandra Mondino; Adriano B L Tort; Nicolás Rubido; Ignacio Carrera; Pablo Torterolo
Journal:  ACS Pharmacol Transl Sci       Date:  2021-01-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.